Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

BACKGROUND O(6)-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or temozolomide. PATIENTS AND METHODS We evaluated the prognostic and predictive value of MGMT methylation testing both in tumor and cell-free circulating DNA (cfDNA) from plasma samples using an ultra-sensitive two-step digital PCR technique (methyl-BEAMing). Results were compared with two established techniques, methylation-specific PCR (MSP) and Bs-pyrosequencing. RESULTS Thresholds for MGMT methylated status for each technique were established in a training set of 98 glioblastoma (GBM) patients. The prognostic and the predictive value of MGMT methylated status was validated in a second cohort of 66 GBM patients treated with temozolomide in which methyl-BEAMing displayed a better specificity than the other techniques. Cutoff values of MGMT methylation specific for metastatic colorectal cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with dacarbazine. In mCRC, both quantitative assays methyl-BEAMing and Bs-pyrosequencing outperformed MSP, providing better prediction of treatment response and improvement in progression-free survival (PFS) (P < 0.001). Ability of methyl-BEAMing to identify responding patients was validated in a cohort of 23 mCRC patients treated with temozolomide and preselected for MGMT methylated status according to MSP. In mCRC patients treated with dacarbazine, exploratory analysis of cfDNA by methyl-BEAMing showed that MGMT methylation was associated with better response and improved median PFS (P = 0.008). CONCLUSIONS Methyl-BEAMing showed high reproducibility, specificity and sensitivity and was applicable to formalin-fixed paraffin-embedded tissues and cfDNA. This study supports the quantitative assessment of MGMT methylation for clinical purposes since it could refine prediction of response to alkylating agents.

[1]  J. J. van den Oord,et al.  MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma , 2015, International journal of cancer.

[2]  T. Wurdinger,et al.  Liquid biopsies in patients with diffuse glioma , 2015, Acta Neuropathologica.

[3]  M. Esteller,et al.  Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation. , 2015 .

[4]  F. D. De Braud,et al.  Role of MGMT as biomarker in colorectal cancer. , 2014, World journal of clinical cases.

[5]  Pieter Wesseling,et al.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. , 2014, Neuro-oncology.

[6]  P. Hurban,et al.  Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. , 2014, Clinical chemistry.

[7]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[8]  Olivier Elemento,et al.  Double-stranded DNA in exosomes: a novel biomarker in cancer detection , 2014, Cell Research.

[9]  R. Soffietti,et al.  MGMT promoter methylation in plasma of glioma patients receiving temozolomide , 2014, Journal of Neuro-Oncology.

[10]  M. Gariboldi,et al.  Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Kramm,et al.  Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells. , 2014, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[12]  Jerry J. Lou,et al.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. , 2013, Neuro-oncology.

[13]  E. Sausville,et al.  A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter , 2013, Molecular Cancer Therapeutics.

[14]  M. Esteller,et al.  Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[15]  P. Álvarez,et al.  MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy , 2012, Journal of Translational Medicine.

[16]  M. Sanson,et al.  Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.

[17]  M. Delorenzi,et al.  MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.

[18]  F. Ducray,et al.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Figer,et al.  Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. J. van den Bent,et al.  First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. , 2011, Neuro-oncology.

[21]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[22]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[23]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[24]  Y. Katayama,et al.  Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. , 2008, International journal of oncology.

[25]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[26]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[27]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[28]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[29]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.